Kenvue的股票下跌了9%,因为未经证实的说法将Tylenol与自闭症和ADHD联系起来,引发了诉讼恐惧,并破坏了潜在的销售。 Kenvue's stock plummeted 9% after unproven claims linked Tylenol to autism and ADHD, sparking litigation fears and derailing potential sales.

Tylenol和Neutrongena的拥有者Kenvue面临越来越多的挑战:积极分子压力、领导力转变,以及将Tylenol的乙氨基苯与自闭症和儿童ADHD联系起来的争议性主张 — — 尽管缺乏科学支持 — — 引发了9%的库存下降并抹去了100亿美元的价值。 Kenvue, owner of Tylenol and Neutrogena, faces mounting challenges as activist pressure, leadership shifts, and a controversial claim linking Tylenol’s acetaminophen to autism and ADHD in children—despite lacking scientific backing—sparked a 9% stock drop and erased $10 billion in value. 由于诉讼风险和销售量下降, 反弹令潜在买家望而却步, 有些人称公司“不可出售”。 The backlash has deterred potential buyers, with some calling the company "unsellable" due to litigation risks and declining sales. 尽管完全出售似乎不太可能, 但仍有兴趣关注其价值60亿至90亿美元的皮肤健康和美容部门, While a full sale seems unlikely, interest remains in its skin health and beauty unit, valued at $6 billion to $9 billion, prompting speculation about a spin-off of non-core brands. 该公司没有对其正在进行的战略审查发表评论。 The company has not commented on its ongoing strategic review.